0.0066USD0.00%Mkt Cap: —P/E: —Last update: 2026-05-22
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-39.22M USD
Revenue/Share—
Last Price0.0066 USD
Fiscal Year End—
MR Quarter—
Employees4
CountryUS
SectorHealth Care
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.00
EPS (TTM)—
EPS (Forward)—
52W Range
0.00660% of range0.0068
52W High0.0068 USD
52W Low0.0066 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE547.06%
ROA-694.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.55M USD
CapEx (TTM)2.40M USD
FCF Margin—
FCF Yield—
Net Debt-734.00K USD
Net Debt/EBITDA0.03
Balance Sheet
Debt/Equity-0.11
Current Ratio0.34
Quick Ratio0.12
Book Value/Sh-77.8160 USD
Cash/Share0.3110 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float2.29M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta1.57
S&P 52W Chg28.31%
Avg Vol (30d)0
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—